http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NZ-603173-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ac2c17e532220d91aca9a28ef60f178b |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-135 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-485 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2095 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61J3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2027 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2031 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 |
| filingDate | 2011-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d629743c5f15fa89eb8f918c2f5809c7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_649d5f57d43f04080b72d377bd82eec6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e144a596ee8e87a5860214174f4b5537 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fa5e02e7cf0803c51fbcb797e3f6968c |
| publicationDate | 2014-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | NZ-603173-A |
| titleOfInvention | Manufacturing of active-free granules and tablets comprising the same |
| abstract | Disclosed herein is a method of manufacturing an oral prolonged release pharmaceutical composition comprising at least the steps of: (a) producing granules comprising at least one prolonged release material selected from the group comprising hydrophobic or hydrophilic polymers, protein-derived material, gums, waxes, oils, fatty acids or fatty alcohols, wherein the granules do not comprise a pharmaceutically active agent; (b) selecting granules of step (a) of substantially uniform size; (c) blending said granules of step (a) or step (b) with at least two pharmaceutically active agents, wherein the first pharmaceutically active agent is an opioid agonist and the second pharmaceutically active agent is an opioid antagonist, and wherein the at least two pharmaceutically active agents are provided as such that they are not comprised within granules; (d) compressing said blended granules of step (c) to obtain an oral prolonged release pharmaceutical composition in the form of a tablet, wherein the opioid agonist is selected from oxycodone, hydromorphone, hydrocodone, tramadol or oxymorphone or their pharmaceutically acceptable salts, hydrates and solvates thereof and wherein the opioid antagonist is selected from naloxone, naltrexone or nalmephene or their pharmaceutically acceptable salts, hydrates and solvates. |
| priorityDate | 2010-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 41.